Rchr
J-GLOBAL ID：201301083890764880   Update date: Sep. 19, 2024

Shimojo Masahito

シモジョウ マサヒト | Shimojo Masahito
Affiliation and department：
Osaka University Graduate School of Pharmaceutical Sciences Advanced Pharmaco-science

About Osaka University Graduate School of Pharmaceutical Sciences Advanced Pharmaco-science


Homepage URL  (2)： http://kaken.nii.ac.jp/d/r/90591925.ja.html ,  https://www.phs.osaka-u.ac.jp/en/research/researcherDetail.php?id=13
Research field  (6)： Molecular biology ,  Medical biochemistry ,  Pharmaceuticals - chemistry and drug development ,  Respiratory medicine ,  Tumor biology ,  Neuroscience - general
Research keywords  (20)： 神経内分泌がん ,  治療抵抗性がん ,  Precision Medicine ,  PM2.5 ,  breast cancer ,  Splicing modifier ,  Companion diagnostics, CDx ,  miR-4516 ,  castration resistant prostate cancer (CRPC) ,  prostate cancer ,  SCLC ,  alternative splicing ,  SRRM4 ,  antisense oligonucleotide ,  nucleic acid medicine ,  iPSC ,  epilepsy ,  Prickle ,  Huntington's Disease ,  REST/NRSF
Research theme for competitive and other funds  (13)：
  • 2022 - 2025 Research on personalized medicine using miR-4516 and antisense oligonucleotide for treating refractory neuroendocrine cancer
  • 2021 - 2022 小細胞肺がん治療に向けた分子標的核酸医薬開発
  • 2017 - 2018 小細胞肺がん治療に向けた分子標的核酸医薬開発
  • 2014 - 2016 Study of novel diagnostic tests and treatment of small cell lung cancer.
  • 2015 - 小細胞肺がん治療を目的とした核酸医薬の探索
Show all
Papers (27)：
  • Hiroto Kohashi, Ryu Nagata, Yusuke Tamenori, Tomorrow Amatani, Yoshifumi Ueda, Yasuo Mori, Yuuya Kasahara, Satoshi Obika, Masahito Shimojo. A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides. Nucleic Acids Research. 2024. 52. 9. 4784-4798
  • Keishiro Mishima, Satoshi Obika, Masahito Shimojo. Splice-switching antisense oligonucleotide controlling tumor suppressor REST is a novel therapeutic medicine for neuroendocrine cancer. Molecular Therapy Nucleic Acids. 2024
  • Misa Yoshida, Chihiro Oda, Keishiro Mishima, Itsuki Tsuji, Satoshi Obika, Masahito Shimojo. An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells. Cancer cell international. 2023. 23. 1. 8-8
  • Shimojo M, Kasahara Y, Inoue M, Tsunoda SI, Shudo Y, Kurata T, Obika S. A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer. Scientific reports. 2019. 9. 1. 7618-7618
  • Yoshie Shudo, Masahito Shimojo, Mikihiko Fukunaga, Seiji Ito. Pituitary adenylate cyclase-activating polypeptide is regulated by alternative splicing of transcriptional repressor REST/NRSF in nerve injury. LIFE SCIENCES. 2015. 143. 174-181
ｍore...
MISC (3)：
Patents (5)：
  • Antisense oligonucleotide for controlling REST expression
  • 細胞内への核酸分子取り込み促進剤、医薬組成物、及び新規化合物
  • 小細胞肺がんの診断薬及び治療薬
  • オリゴヌクレオチドを含有する小細胞肺癌治療薬
  • REST mRNA前駆体のプロセシングにおけるNエキソンのスキッピングを誘導するオリゴヌクレオチド
Books (3)：
  • Encyclopedia of Cancer Chapter Title: RE1-Silencing Transcription Factor Edited by Dr. Manfred Schwab
    Springer 2017
  • 痛みの可塑性と慢性化 特集痛みとしびれのサイエンス-基礎と臨床
    脊椎脊髄ジャーナル 2011
  • Chapter 20 - Regulation of cholinergic gene expression by NRSF/REST Cholinergic Mechanisms: Function and Dysfunction
    CRC Press 2004 ISBN:1841840750
Lectures and oral presentations  (25)：
  • 小細胞肺がん治療を目的としたアンチセンス核酸SRRM4-ASOの体内動態について
    (日本薬学会第143年会 2023)
  • アンチセンス活性向上を目的としたgapmer型アンチセンス核酸のデザイン戦略
    (日本薬学会第143年会 2023)
  • TRPC3/C6チャネル活性化剤を用いたアンチセンス核酸の細胞内取り込みに関する研究
    (日本薬学会第143年会 2023)
  • 悪性脳腫瘍治療を志向した転写因子RESTに対するギャップマー型アンチセンス核酸の開発
    (日本薬学会第143年会 2023)
  • Development of splice-switching oligonucleotides (SSOs) that control the tumor suppressor REST
    (18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 2022)
ｍore...
Education (4)：
  • 1992 - 1995 Nagasaki University Graduate School of Pharmaceutical Sciences
  • 1990 - 1992 Nagasaki University Graduate School of Pharmaceutical Sciences
  • 1986 - 1990 Nagasaki University Pharmaceutical Sciences
  • 1986 - 1990 Nagasaki University School of Pharmaceutical Sciences
Professional career (1)：
  • 博士(薬学) (長崎大学)
Work history (7)：
  • 2016/07 - 現在 Osaka University School of Pharmaceutical Sciences
  • 2024/12 - 2024/12 Osaka University Graduate School of Pharmaceutical Sciences Associate Professor
  • 2015/07 - 2016/03 Osaka Medical College Faculty of Medicine
  • 2010/06 - 2015/06 Kansai Medical University Faculty of Medicine
  • 2002/12 - 2010/05 University of Kentucky College of Medicine Assistant Professor
Show all
Committee career (4)：
  • 2014/10 - 現在 Austin Journal of Cancer and Clinical Research
  • 2014/09 - 現在 Austin Journal of Lung Cancer Research Editorial Board
  • 2014/09 - 2016/03 Edorium Journal of Biochemistry Editor-in-Chief
  • 2012 - 2016/03 Scientifica Editorial Board
Awards (1)：
  • 2020/04 - Public Interest Incorporated Foundation Kiyoko Goto and Paul Bourdarie Cancer Foundation The 8th Kiyoko and Paul Bourdarie-Goto Scientific Prize A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer (Scientific Reports volume 9, Article number: 7618 (2019))
Association Membership(s) (4)：
Japanese Cancer Association ,  THE MOLECULAR BIOLOGY SOCIETY OF JAPAN ,  American Society for Biochemistry & Molecular Biology ,  Society for Neuroscience
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM